



GB
04382

The
Patent
Office

PCT/GB 99 / 0 4 3 8 2



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 27 JAN 2000

WIPO PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

097868918

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

L. Mahoney

Signed

Dated 13 January 2000

THIS PAGE BLANK (USPTO)

Patents Act 1977
(Rule 16)

PATENT OFFICE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	SJK/BP5638101		
2. Patent application number (The Patent Office will fill in this part)	GB 9828564.6		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	RADEMACHER GROUP LIMITED BOUVERIE HOUSE 154 FLEET STREET LONDON EC4A 2HX GB		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation	75 76036001		
4. Title of the invention	MATERIALS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER		
5. Name of your agent (if you have one)	MEWBURN ELLIS		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	YORK HOUSE 23 KINGSWAY LONDON WC2B 6HP		
Patents ADP number (if you know it)	109006	✓	
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form 0

Description 25

Claim(s) 0

Abstract 0

Drawing(s) 11 + 11

10. If you are also filing any of the following, state

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents 0
(Please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Simon J. Kiddle

Date

23/12/98

12. Name and daytime telephone number of person to contact in the United Kingdom
SIMON J. KIDDLE 0117 926 6411

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Materials and Methods for the Treatment and Diagnosis of Cancer

Field of the Invention

5 The present invention relates to materials and methods
for the treatment and diagnosis of cancer.

Background of the Invention

10 It has been observed that when tumour cells are grown in
culture, the rate of proliferation of the cells depends
on the cell density in the culture. It has been
hypothesised that this increase in the rate of
proliferation as the number of cells increases is due to
the presence of tumour autocrine factors (TAFs) in the
15 cell supernatant. TAFs are believed to be growth factors
produced by the tumour cells which cause them to
proliferate in the absence of external stimuli such as
hormones.

20 There is some experimental evidence supporting the
existence of TAFs in the culture supernatant. If the
supernatant from a high density tumour cell culture is
applied to a dilute culture, the rate of proliferation of
the cells in the dilute culture quickly accelerates to
25 the level associated with cells in a high density
culture. It has also been observed that if the
supernatant is boiled prior to addition to the dilute
culture, the acceleration in the proliferation rate of
the cells is not observed.

30 Witter et al (1987) have reported that conditioned medium
from Reuber H-35 or Fao hepatoma cells contained
autocrine factors that both stimulated DNA synthesis and
activated acetyl-coenzyme A (CoA) carboxylase in serum
35 deprived cells. They also found that the factors
increased the cell number and mitotic index in tumour
cell cultures. The investigators fractionated
conditioned medium from H-35 hepatoma cells and found
that two low molecular weight components (MW < 1000) co-

purified with the activity of increasing DNA synthesis. Radiolabelling incorporation studies suggested the possible incorporation of glucosamine and galactose, but no incorporation of *myo*-inositol or mannose. However, the authors were unable to purify, isolate or characterise the autocrine factor from conditioned medium and do not provide any definite suggestions as to the structure or activity of their autocrine factor.

Summary of the Invention

Broadly, the present invention is based on the isolation and identification of TAFs, and in particular on the finding that TAFs are inositolphosphoglycans (IPGs) such as A or P-type IPGs. In particular, the results show that the TAFs include *myo*-inositol and by extension A-type IPGs.

Accordingly, in a first aspect, the present invention provides the use of an IPG antagonist for the preparation of a medicament for the treatment of cancer.

In the present application, "IPG antagonists" includes substances which have one or more of the following properties:

(a) substances capable of inhibiting release of IPGs, e.g. inhibitors of enzymes which cause their release such as glycosylphosphatidylinositol specific phospholipases (GPI-PL);

(b) substances capable of reducing the levels of IPGs by binding to them, e.g. anti-IPG antibodies; and/or,

(c) substances capable of reducing the effects of IPGs, e.g. competitive antagonists such as IPGs which are biologically inactive in the species in which they are used, e.g. the use of porcine liver A-type IPGs in humans.

In preferred embodiments, the IPG antagonist is an antibody capable of specifically binding IPGs and preferably which does not cross-react with the common reactive determinant of GPI anchored proteins.

5 Preferably, the antibody is a monoclonal antibody, examples of which are disclosed below.

10 In other embodiments, the antagonist inhibits the release of IPGs. Figure 4 shows that IPGs which are tumour autocrine factors contain cyclic phosphate. This suggests that an enzyme responsible for the release of the IPG TAFs is a GPI-PLC, which has not been previously identified in mammalian tissues. Therefore, inhibitors of GPI-PLC may be used as IPG antagonists for treatment
15 of cancer.

In a further aspect, the present invention provides a method of diagnosing cancer comprising determining the presence or level of IPGs in a biological sample from a
20 patient. The presence or level of IPGs will typically be compared to standards from healthy and cancerous tissues. Preferably, the presence or level of the IPGs is determined by measuring a characteristic activity of an A or P-type IPG, details of which are set out below.
25 Alternatively, the presence or level of a characteristic component of IPGs and in particular IPG TAFs, e.g. cyclic phosphate, could be used as a diagnostic marker. Other components of IPGs that might be used as diagnostic markers are set out below.

30

In a further aspect, the present invention provides the use of cellulose column chromatography in the purification of IPGs.

35

In a further aspect, the present invention provides a method of purifying or isolating IPGs, the method comprising making contacting a sample containing IPGs

with a column containing cellulose, and eluting the IPGs from the column. Preferred conditions preparing the column and eluting IPG containing fractions are set out below.

5

Embodiments of the present invention will now be described by way of example and not by limitation with reference to the accompanying figures.

10 Brief Description of the Figures

Figure 1 shows the fractionation of conditioned medium by cellulose column chromatography. The results are presented as counts per minute (cpm) per fraction. The arrows indicate the solvent system used at a particular fraction.

15

Figure 2 shows the effects on DNA synthesis of conditioned medium. Conditioned medium at two different concentrations (10% and 20%) was assayed for stimulating activity in test FaO cells. The results are presented as radioactivity (cpm) obtained after incorporation of ³H-thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition), and the fractions obtained. The arrows indicate the eluent system used at a particular fraction.

20

25

Figure 3 shows phosphate analysis of conditioned medium fractionated by cellulose column chromatography. Results are presented as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction.

30

Figure 4 shows the mass spectrum of fraction 21 from the cellulose purification of conditioned medium.

35

Figure 5 shows the effect on the proliferation of FaO cells of conditioned medium treated with anti-IPG monoclonal antibodies. Results are presented as

radioactivity (cpm) obtained after incorporation of ^3H -thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition), and samples containing the antibodies.

5

Figures 6 and 7 show rat liver IPGs A and P fractionation profiles. The results are shown as radioactivity (cpm) obtained after incorporation of ^3H -thymidine into DNA of 3T3EFGTR17 cells, for control (no serum addition), FCS (10% foetal calf addition), and fractions. All fractions were assayed at a final concentration of 1/80, except for fraction 26 of IPG-P (Fig. 6) which was also tested at a final concentration of 1/40 and 1/160. All fractions of the IPG-A (Fig. 7) were tested at a final concentration of 1/80. The arrows indicate the eluent system used at a particular fraction.

10

15

20

Figure 8 shows the phosphate analysis of rat liver IPG-P fractionated from rat liver by cellulose column chromatography. Results are presented as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction.

Detailed Description of the Invention

25

IPGs

30

35

Studies have shown that A-type mediators modulate the activity of a number of insulin-dependent enzymes such as CAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and CAMP phospho-diesterases (stimulates). In contrast, P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates), glycogen synthase phosphatase (stimulates) and CAMP dependent protein kinase (inhibits). The A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators are mitogenic

when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF-receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.

Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. A- and P-type IPG biological activity has also been detected in human liver and placenta, malaria parasitized RBC and mycobacteria. The ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features.

A-type substances are cyclitol-containing carbohydrates, also containing Zn^{2+} ion and optionally phosphate and having the properties of regulating lipogenic activity and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium, and stimulate lipogenesis in adipocytes.

P-type substances are cyclitol-containing carbohydrates, also containing Mn^{2+} and/or Zn^{2+} ions and optionally phosphate and having the properties of regulating glycogen metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and stimulate pyruvate dehydrogenase phosphatase.

Methods for obtaining A-type and P-type IPGs are set out

in Caro et al, 1997, and in WO98/11116 and WO98/11117. In summary, the methods disclosed in these applications involve:

(a) making an extract by heat and acid treatment of
5 IPG source material;

(b) after centrifugation and charcoal treatment, allowing the resulting solution to interact overnight with an AG1-X8 (formate form) anion exchange resin;

(c) collecting a fraction having A-type IPG
10 activity obtained by eluting the column with 50 mM HCl and/or collecting a fraction having P-type IPG activity obtained by eluting the column with 10mM HCl;

(d) neutralising to pH 4 (not to exceed pH 7.8) and lyophilising the fraction to isolate the substance;

15 (e) employing descending paper chromatography using 4/1/1 butanol/ethanol/water as solvent;

(f) purification using high-voltage paper electrophoresis in pyridine/acetic acid/water; and,

(g) purification using Dionex anion exchange
20 chromatography or purification and isolation using Vydac HPLC chromatography to obtain the isolated IPG.

As disclosed herein, it is also possible to employ column
25 chromatography using cellulose, and especially microcrystalline cellulose, in the isolation or purification of IPGs. Exemplary conditions are provided in the experimental section below.

Antagonists

30 In the present invention, "IPG antagonists" includes substances which have one or more of the following properties:

(a) substances capable of inhibiting release of
35 IPGs, e.g. inhibitors of enzymes which cause their release such as GPI-PL;

(b) substances capable of reducing the levels of IPGs by binding to them, e.g. anti-IPG antibodies;

and/or,

(c) substances capable of reducing the effects of IPGs, e.g. competitive antagonists such as IPGs which are biologically inactive in the species in which they are used, e.g. the use of A-type IPGs as obtainable from porcine liver in humans.

Examples of IPG antagonists of type (b) include specific binding proteins, e.g. naturally occurring specific binding proteins that can be obtained by screening biological materials for substances that bind to IPGs.

In a further example, the antagonists are antibodies capable of specifically binding to IPGs. The production of polyclonal and monoclonal antibodies is well established in the art. Examples of anti-IPG monoclonal antibodies are produced by hybridoma cell lines 2F7, 2D1 and 5H6 deposited at European Collection of Cell Cultures (ECACC) under accession numbers 98051201, 98031212 and 98030901 on 12 May 1998 ('201) and 9 March 1998 ('212 and '901).

Monoclonal antibodies are particularly useful as they can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP 0 184 187 A, GB 2 188 638 A or EP 0 239 400 A. A hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with an immunogen, e.g. an IPG or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, Nature, 357:80-82, 1992). Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of sacrificing the animal.

As an alternative or supplement to immunising a mammal with an IPG, an antibody specific for the IPG may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus, antagonist antibodies includes antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimics that of an antibody enabling it to bind an antigen or epitope.

Examples of antibody fragments which capable of binding an IPG or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single

arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')₂ fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

The antibodies described above may also be employed in the diagnostic aspects of the invention by tagging them with a label or reporter molecule which can directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.

One favoured mode is by covalent linkage of each antibody with an individual fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline

phosphatase detection systems may be employed.

In a further embodiment, the IPG antagonists are competitive antagonists, such as synthetic compounds or IPGs which are biologically inactive in the relevant respect, e.g IPGs which do not have a TAF activity such as enhancing the proliferation of tumour cells. An example of this latter type of antagonist is the use of porcine liver A-type IPGs in humans. Synthetic compounds may be produced by chemical techniques or using combinatorial chemistry, and then screened for IPG antagonist activity. These compounds may be useful in themselves or may be used in the design of mimetics, providing candidate lead compounds for development as pharmaceuticals. Synthetic compounds might be desirable where they are comparatively easy to synthesize or where they have properties that make them suitable for administration as pharmaceuticals, e.g. antagonist which are peptides may be unsuitable active agents for oral compositions if they are degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing is generally used to avoid randomly screening large number of molecules for a target property.

Pharmaceutical Compositions

IPGs or IPG antagonists can be formulated in pharmaceutical compositions. These compositions may comprise, in addition to one or more of IPGs or antagonists, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Whether it is a polypeptide, antibody, peptide, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of

delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A. (ed), 1980.

The compositions may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Thus, in the treatment of cancer, the IPG antagonists can be administered in combination with other chemotherapy or radiotherapy.

Diagnostic Methods

Methods for determining the concentration of analytes in biological samples from individuals are well known in the art and can be employed in the context of the present invention to determine whether an individual has an elevated level of IPGs, and so has or is at risk of cancer. The purpose of such analysis may be used for diagnosis or prognosis to assist a physician in determining the severity or likely course of the pre-eclampsia and/or to optimise treatment of it. Examples of diagnostic methods are described in the experimental section below.

Preferred diagnostic methods rely on the detection of IPGs, employing biological samples such as blood, serum, tissue samples (especially from a suspected tumour site), or urine.

The assay methods for determining the concentration of IPGs typically employ a binding agent having binding sites capable of specifically binding to the IPGs in preference to other molecules. Examples of binding agents include antibodies (examples of which are provided above), receptors and other molecules capable of

specifically binding IPGs. Conveniently, the binding agent is immobilised on solid support, e.g. at a defined location, to make it easy to manipulate during the assay.

5 The sample is generally contacted with a binding agent under appropriate conditions so that IPGs present in the sample can bind to the binding agent. The fractional occupancy of the binding sites of the binding agent can then be determined using a developing agent or agents.
10 Typically, the developing agents are labelled (e.g. with radioactive, fluorescent or enzyme labels) so that they can be detected using techniques well known in the art. Thus, radioactive labels can be detected using a scintillation counter or other radiation counting device,
15 fluorescent labels using a laser and confocal microscope, and enzyme labels by the action of an enzyme label on a substrate, typically to produce a colour change. The developing agent can be used in a competitive method in which the developing agent competes with the analyte
20 (IPG) for occupied binding sites of the binding agent, or non-competitive method, in which the labelled developing agent binds analyte bound by the binding agent or to occupied binding sites. Both methods provide an indication of the number of the binding sites occupied by
25 the analyte, and hence the concentration of the analyte in the sample, e.g. by comparison with standards obtained using samples containing known concentrations of the analyte.

30 Materials and Methods

Anti-IPG Antibodies

Anti-IPG antibodies were produced by culturing hybridoma cell lines 2F7, 2D1 and 5H6 deposited at European Collection of Cell Cultures (ECACC) under accession
35 numbers 98051201, 98031212 and 98030901, and isolating the anti-IPG antibodies thus produced.

Cellulose Purification of IPGs

Microcrystalline cellulose (Merck Avicel®) was fined by suspension in double-distilled water followed by standing for 10 minutes and decanting of the unsettled suspension.

5 After 12 repeats, the settled material was shaken vigorously with two volumes of fresh water and poured into the top of a Pharmacia® glass column of 16 mm i.d. with the top plunger removed. Water was allowed to flow out under gravity at 3 ml/min. After allowing the
10 solvent level to drop to the top of the packed bed, the plunger was replaced and water pumped through the column at 5 ml/min using a Pharmacia® peristaltic pump. The column was treated with the following solvents:

15	Water	150ml
	50% aqueous methanol	50ml
	Methanol	50ml
	Butanol/methanol/water (4:1:1)	150ml

20 All solvents were degassed prior to use by brief swirling under vacuum. After the final solvent, the plunger was removed, and the solvent level allowed to drop to the top of the packed bed under gravity, whereupon flow was stopped.

25 The sample (2 ml of conditioned cell medium or IPG extract from two rat livers) was swirled for 5 minutes with 2 ml of the cellulose suspension and the entire mixture lyophilised.

30 The dry cellulose material was suspended in 2ml of butanol/ethanol/water (B:W:E) (4:1:1) and applied gently and evenly to the top of the packed bed. The remaining material was washed in using a further 2ml of the
35 solvent. The solvent level was again dropped to the bed level before commencing pumping with B:W:E (4:1:1) at 5 ml/min. Fractions were collected in glass vessels as

follows, either by hand into flasks or using a Gilson model 204 fraction collector set to 1 minute/tube:

Butanol/methanol/water (4:1:1)	150ml
Methanol	50ml
50% aqueous methanol	10 x 5ml fractions
Water	20 x 5ml fractions
HCl(aq.) pH 1.3	10 x 5ml fractions
HCl(aq.) pH 1.3	75ml

The samples were evaporated to dryness using a rotary evaporator or Speedvac at below 30°C. Samples were dissolved in 200µl of water and stored at -20°C.

Preparation of conditioned medium (CM) from H4TIE cells

(a) H4TIE cells were cultured on 75 cm² Falcon cap vented tissue culture flasks at cell density of $2-6 \times 10^4$ cells/cm² using DMEM (Gibco Cat. No. 31885), supplemented at 5% with a 1:1 mixture of foetal calf serum and heat inactivated calf serum and incubate at 37°C, 5% CO₂ atmosphere until 100% confluence.

(b) At confluence ($15-17 \times 10^6$ cells/T75 flask), the cells were washed twice using 15-20 mL Hank's Balance Salt Solution pH 7.4 (HBSS, Gibco Cat No. 14174-053) and 5ml Trypsin-EDTA solution (Sigma Cat. No. T 4171) was added. Care was taken to ensure that the whole flask surface was completely covered by the solution. The excess of Trypsin was then removed, leaving in the flask only 2 ml of liquid which was then incubated for 10 min.

(c) When the cells detached, 8 ml of growth medium was added and the mixture was centrifuged for 5 min at 1000 rpm. The supernatant was discharged and the pellet resuspended by adding 10 ml growth medium. The cell suspension was transferred into a sterile 25 ml universal container, 10 ml of the same medium was added, the cap

closed tightly and the container rocked several times to produce a homogeneous cell suspension.

(d) The cells were subcultured 1/10 or 1/20 ($1-2.5 \times 10^4/\text{cm}^2$) in 75 cm^2 Falcon cap vented flask, using the same medium and incubation conditions described in step (a). When the cells seeded at 1/10 reached 70% confluence ($11.5-12.0 \times 10^6$ cells/ T75 flask, normally 3 days after), the culture was washed three times with 20 ml serum free DMEM and then incubated for 3 hours. This procedure was repeated twice.

(e) The culture was incubated for 48 hr at 37°C , 5% CO_2 atmosphere, and then the conditioned medium was transferred into a centrifuge tube, and cell debris removed by centrifugation at 1000g for 10 min at 4°C and then at 105,000 g for 60 min at 4°C . The supernatant was sterilized by filtration and stored at -80°C .

Biosynthetic labelling and extraction of conditioned medium

(a) H4IIE cells grown to 50-60% confluence in T75 cap vented flask Falcon (Falcon Cat. No F3111) ($8-9 \times 10^6$ cells/T75 flask) in DMEM medium, supplemented with 5% foetal calf serum and 5% heat inactivated calf serum, were washed twice using HBSS at 37°C . 10 mL of fresh growth medium was added and then 250 Ci of the ^3H -labelled precursors (Glucosamine, Galactose, Mannose and myo-Inositol). The culture was incubated at 37°C , 5% CO_2 atmosphere for 24 hours.

(b) After 24 hours, the cells were washed three times as described in step (d) above and the cells incubated and the medium harvested as in step (e).

(c) The supernatants obtained were adjusted to pH 3.0 with HCl (c), and prewashed activated charcoal (25 mg/mL)

added and stirred at 4°C for 30 min. The suspension was transferred into centrifuge tubes and the charcoal spun down by centrifugation at 20,000 g for 30 min at 4°C.

- 5 (d) The supernatant was sterilized using a 0.2 µm pore size filter and stored at 4°C. If it was not required for immediate use, it was freeze-dried and kept at -80°C until needed.

10 **Bioactivity assay of H4IIE conditioned medium by measuring the proliferation of FaO cells**

- 15 (a) FaO cells grown at 60-70% confluence in T75 Falcon cap-vented tissue culture flasks Gibco Cat.No F3111 with RPMI-1640 (Gibco Cat. No. 21875), supplemented at 5% with a 1:1 mixture of foetal calf serum and heat inactivated calf serum were washed twice with 20 ml of HBSS pH 7.4 (Gibco Cat. No. 14174). The cells were detached with Trypsin-EDTA solution (Sigma Cat. No. T4171) as described in steps (b) and (c) of "Preparation of conditioned medium from H4IIE" protocol set out above.
- 20

- (b) The cell suspension was counted twice and the required volume to dilute the suspension at a density of $2.5-3.0 \times 10^3$ cell/ml was calculated. The calculated volume of growth medium was added and the cells were transferred into a sterile 25 ml universal container. The container was rocked gently several times to produce a homogenous cell suspension.
- 25

- 30 (c) The cells were plated in a 96-wells Falcon U bottom shape microwell plate by adding 100 µl of cell suspension per well and incubated at 37°C in a 5% CO₂ atmosphere incubator. After 24 hours, each well was washed three times with 100 µl of serum free medium and incubates for a further 24 hours.
- 35

- (d) The medium was replaced by adding serum free medium

and the cells incubated for three additional hours. Meanwhile, the IPG samples or medium supplementation at different concentrations (ranging from 1% to 20.0%) of H4IIE conditioned medium were prepared. 100 µl serum free medium was added to the controls, 100 µl completed growth medium was added to the positive controls and 100 µl of medium supplemented with H4IIE conditioned medium.

(e) The cells were incubated at 37°C in a 5% CO₂ atmosphere incubator for 18 hours and then 1 Ci ³H-thymidine was added to each well. After 4 hours incubation, the radioactive medium was removed and replaced with 50 µl trypsin-EDTA solution. The cells were incubated for 10 min and the DNA collected on filters (Helis Bio Ltd. Cat No 11731) using a cell harvester (SKATRON 12 well/cell harvester). The filters were transferred to scintillation vials, 2 ml of scintillation cocktail was added to each vial and counted for one minute in a Beckman scintillation counter.

Assays

Phosphate analysis and PDH activation assays were carried out as described in Caro et al, 1997.

Results

Fractionation of conditioned medium by cellulose column chromatography

Conditioned medium biosynthetically labelled with ³H myo-inositol (squares), glucosamine (circles) or galactose (open circles) at 1.35E5, 2.85E5 and 2.50E5 cpm respectively, obtained as described in Methods, was separated by cellulose column chromatography, 5 ml fractions were collected and 200 µl counted in a Beckman liquid scintillation counter. The results are presented in figure 1 as counts per minute (cpm) per fraction. The arrows indicate the solvent system used at a particular fraction. The results in figure 1 show that these

radioactive components are incorporated into TAF fractions obtained from the supernatant and that the TAF fractions can be isolated by the same procedures as IPGs.

5 Effects on DNA synthesis of conditioned medium

Conditioned medium at two different concentrations (10% and 20%) was assayed for stimulating activity in test Fao cells, as under Methods. The fractions obtained by purification of conditioned medium (2 ml) by cellulose column chromatography were concentrated to dryness, dissolved in water (200 μ l), and also assessed for activity (4 μ l). The results are presented in figure 2 as radioactivity (cpm) obtained after incorporation of ^3H -thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition), and the fractions obtained. The arrows indicate the eluent system used at a particular fraction. The results show that some of the fractions, and in particular fraction 21 causes proliferation of Fao cells as does the addition of conditioned medium.

Phosphate analysis of conditioned medium

Conditioned medium (2 ml) was fractionated by column chromatography using cellulose as described under methods. Fractions (5 ml) were collected, concentrated to dryness, dissolved in water (200 μ l) and a portion (10 μ l) was assayed for phosphate as described in Caro et al, 1997. Briefly, samples were evaporated to dryness and hydrolized with perchloric acid (70% by volume) at 180°C for 30 min. After cooling at room temperature, distilled water (250 μ l) was added. Ammonium molibdate and ascorbic acid were sequentially added, yielding final concentrations of 3 and 72 mM, respectively. Colour development was achieved by heating at 95°C for 15 min. Optical absorbance was measured at 650 nm. The results are presented in figure 3 as OD obtained per fraction. Arrows indicate the eluent system used at a particular

fraction. The results show that the fractions co-purifying with TAF activity contain phosphate, supporting the fact that TAFs are IPGs.

5 Mass spectrum of fraction 21

Conditioned medium (2 ml) was fractionated by column chromatography using cellulose as described under Methods. Fractions (5 ml) were collected, concentrated to dryness, dissolved in water (200 μ l). After assaying the biological activity of each fraction, a portion of fraction 21 (50 μ l) was taken and diluted to 100 μ l with methanol (25 μ l) and water (25 μ l containing 1% acetic acid). Mass spectra was preformed on an Ionspec FTMS instrument equipped with a 4.7 T magnet and a heated capillary external ESI source. The base pressure in the analyser region was maintained at $2\text{E}-10$ Torr. The solutions were electrosprayed from a 33 gauge syringe at a flow rate of 1.5 ml/min (Harvard Apparatus 22 syringe pump) into a heated metal capillary (135V), and skimmer (35V), using nitrogen at 235°C as drying gas.

Mass spectrum of fraction 21:

Losses of 82 m/u	PO_3H_3
Losses of 16 m/u	$-\text{NH}_2$

Other important signals:

m/z 427	Hexosamine-Inositol-CP-Na
m/z 509	[Hexosamine-Inositol-CP-Na] + PO_3H_3
m/z 591	[Hexosamine-Inositol-CP-Na] + 2(PO_3H_3)
m/z 345	Hexosamine-Inositol-CP-Na - PO_3H_3

Effect on the proliferation of FaO cells of conditioned medium treated with anti-IPG monoclonal antibodies

Test FaO cells were used to measure the stimulating activity of conditioned medium as described in methods, in the presence of the anti-IPG monoclonal antibodies 2D1, 5H6 and 2F1 at a concentration of 1 μ g per well. The

results in figure 5 are presented as radioactivity (cpm) obtained after incorporation of ^3H -thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition) and samples containing the antibodies. The results show that all three antibodies antagonise the proliferating activity caused by the addition of conditioned medium to the Fao cells, and that antibody 2F1 had the greatest inhibitory effect.

10 Rat liver IPGs A and P fractionation profiles

The IPGs obtained from two rat livers were fractionated using cellulose column chromatography as described in Methods. The fractions obtained were evaporated to dryness, redissolved in water (200 μl), and a portion of the solution (1.25 μl) assayed for biological activity in triplicates. The results are shown as radioactivity (cpm) obtained after incorporation of ^3H -thymidine into DNA of 3T3EFGTR17 cells, for control (no serum addition), FCS (10% foetal calf addition), and fractions. All fractions were assayed at a final concentration of 1/80, except for fraction 26 of IPG-P (Figure 6) which was also tested at a final concentration of 1/40 and 1/160. All fractions of the IPG-A (Figure 7) were tested at a final concentration of 1/80. The arrows indicate the eluent system used at a particular fraction. The results indicate that cellulose chromatography is an effective technique for the isolation and purification of IPGs, e.g. IPGs obtained from natural source materials.

30 PDH activity of Fraction 26 of IPG-P type

PDH activity was measured as described in Caro et al, 1997. A portion (10 ml) of fractions 22, 26 and 27 was assayed. The result is presented as activation of the PDH complex expressed as units per gram of tissue. One unit of IPG PDH activity is the amount required to increase the basal rate of NADH production by 50%.

Fraction 22 = 0.123 units/g

Fraction 26 = 2.09 units/g

Fraction 27 = 0.523 units/g.

- 5 The results show that the IPGs purified from rat liver using cellulose chromatography have a characteristic P-type IPG biological activity.

Phosphate analysis of rat liver IPG-P

- 10 The IPG-P obtained from two rat livers was fractionated by column chromatography using cellulose as described under Methods. Fractions (5 ml) were collected, concentrated to dryness, dissolved in water (200 µl) and a portion (100 µl) was assayed for phosphate as described
15 in Caro et al, 1997. Each fraction was evaporated to dryness and hydrolized with perchloric acid (70% by volume) at 180°C for 30 min. After cooling at room temperature, distilled water (250 µl) was added. Ammonium molibdate and ascorbic acid were sequentially
20 added, yielding final concentrations of 3 and 72 mM, respectively. Colour development was achieved by heating at 95°C for 15 min. Optical absorbance was measured at 650 nm. The results in figure 8 are presented as OD obtained per fraction. Arrows indicate the eluent system
25 used at a particular fraction. The results show that the P-type IPGs purified using cellulose chromatography contain phosphate.

Deposits

- 30 The deposit of hybridomas 2F7, 2D1 and 5H6 in support of this application was made at the European Collection of Cell Cultures (ECACC) under the Budapest Treaty by Rademacher Group Limited (RGL), The Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK. The deposits have
35 been accorded accession numbers accession numbers 98051201, 98031212 and 98030901 on 12 May 1998 ('201) and 9 March 1998 ('212 and '901). RGL give their unreserved

and irrevocable consent to the the materials being made available to the public in accordance with appropriate national laws governing the deposit of these materials, such as Rules 28 and 28a EPC. The expert solution under Rule 28(4) EPC is also hereby requested.

References:

The references referred to herein are expressly incorporated by reference.

5 WO98/11116 and WO98/11117 (Hoeft Rademacher Limited).


Rademacher et al, Brazilian J. Med. Biol. Res., 27:327-341, 1994.

10 Caro et al, Biochem. Mol. Med., 61:214-228, 1997.

Witters et al, J. Bio. Chem., 263:8027-8036, 1986.

THIS PAGE BLANK (USPTO)


Figure 1A



THIS PAGE BLANK (USPTO)

2/11

Figure 1B




THIS PAGE BLANK (USPTO)

3/11

Proliferation assay - FaO cells


Figure 2



THIS PAGE BLANK (USPTO)

Figure 3

H4 Conditioned Medium Fractionation - Phosphate Analysis




THIS PAGE BLANK (USPTO)

Figure 4



File: c:\ionspec\esidata\MS980928.004
CM cellulose fractionation-fraction 21

Date: 28-SEP-1998
Time: 12:05:32
Mode: Positive
Scans: 50
Scale: 143.8911




5 / 11

THIS PAGE BLANK (USPTO)

Figure


Effects of mAb on H4IIE Conditioned Medium
Cell proliferation (FaO cells)



THIS PAGE BLANK (USPTO)

Figure 6


Proliferation Assay - Liver IGP P - Fibroblasts cells



THIS PAGE BLANK (USPTO)

Fig. 1

Proliferation Assay - Liver IPG A - Fibroblasts cells




11/8

THIS PAGE BLANK (USPTO)

Figure 1


Proliferation Assay - Liver IPG A - Fibroblasts cells



THIS PAGE BLANK (USPTO)

Fig. 28A

Liver IPG P - Cellulose Purification- Phosphate Analysis




10/11

THIS PAGE BLANK (USPTO)

Figure 68

Liver IPG P - Cellulose Purification- Phosphate Analysis



PCT/98 04382

23.12.99

newburn Ellis

THIS PAGE BLANK (USPTO)